Liquid Stable Kit Determines Homocysteine in Serum and Plasma
|
By LabMedica International staff writers Posted on 20 Jun 2012 |
A liquid stable homocysteine kit provides a convenient and accurate method for the determination of homocysteine in human serum and plasma. Homocysteine is an indicator of a number of disease markers and should be an integral part of a laboratory’s testing menu.
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Latest Clinical Chem. News
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
- Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
- At-Home Blood and Cognitive Tests Support Dementia Risk Stratification
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Channels
Molecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more




.jpg)



